Condition: Advanced Colorectal Cancer · Sponsor: Lepu Biopharma Co., Ltd.
This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.
This description comes directly from the study's public registry record.
Program Director · 86-21- 67680899 · ra_bj@lepubiopharma.com
Always discuss trial participation with your own doctor first.
| Peking University cancer Hospital | Beijing, Beijing Municipality, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07737600